JBA AI Earns FDA SaMD Recognition
A New Era of Accessible Health Monitoring
GARDEN GROVE, CALIFORNIA / ACCESS Newswire / June 9, 2025 / JBA AI, the flagship health-tech division under AQ Pharmaceuticals, Inc. and JBA Brands, proudly announces several major global milestones in its mission to make preventive healthcare more accessible, intelligent, and affordable.JBA AI Infographic
JBA AI has been officially recognized by the United States Food and Drug Administration (FDA) as a Software as a Medical Device (SaMD). In addition, the platform has now received Class B Medical Device approval from Vietnam's Ministry of Health. These achievements affirm the platform's safety, clinical effectiveness, and international credibility.
The JBA AI mobile application is already available globally for Android users and will soon be released on iOS. It enables contactless, non-invasive vital signs monitoring directly through smartphones or tablets. In just 60 seconds, the app delivers insights on over nine key health metrics. These include heart rate, heart rate variability, blood oxygen saturation, respiratory rate, stress index, and estimated glucose and blood pressure trends. This is achieved using AI-powered facial signal analysis through camera-based remote photoplethysmography technology.
Expanding its impact even further, JBA AI has partnered with one of Vietnam's largest financial institutions, which serves more than 30 millions members. Together, they are preparing to launch JBA AI nationwide, making preventive health monitoring more accessible through a trusted and widespread digital network.
'JBA AI is more than a health app - it's a certified medical device. Recognized by both the FDA and Vietnam's Ministry of Health,' said Tracy Trang Nguyen, founder and CEO of JBA AI. 'We're proud to deliver trusted, clinically guided tools for daily health monitoring worldwide.'
Nguyen is a Vietnamese American engineer and wellness industry leader who developed JBA AI after surviving cancer. Her personal health journey inspired her to combine advanced artificial intelligence with affordable wellness solutions. Under her leadership, JBA AI complements other products within the JBA Brands portfolio, such as GlucoTrojan, Joint Revive Fucoidan, and Vegan Collagen, to form a fully integrated health ecosystem.
JBA AI is already gaining traction and is starting to expand into pharmacies, corporate wellness programs, public health campaigns, and family clinics across the United States, Vietnam, and other countries. The platform's franchise-ready model supports rapid local deployment while keeping costs low and impact high. It is designed to help people monitor their health in real-time, without the need for needles, wearable devices or clinic visits.
JBA AI is currently welcoming franchisees, affiliates, and institutional partners to help bring this technology to communities around the world. Whether at home or in partnership with healthcare providers, JBA AI is redefining preventive care through data-driven technology and a compassionate approach to well-being.
Contact Information
Catherine Marino
Marketing Manager
[email protected]
(+1) 714 903 1009
SOURCE: AQP One, Inc.
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Blueprint MCAT Raises the Bar--and Lowers the Price--on Medical School Prep
Blueprint MCAT doubles down on accessibility and outcomes amid rising competitiveness in medical school admissions. LOS ANGELES, June 11, 2025 /PRNewswire/ -- In response to the rising competitiveness of medical school admissions and the increasing pressure on students to achieve top MCAT scores, Blueprint MCAT has announced sweeping updates to its course offerings, designed to make MCAT test prep more affordable, effective, and accessible than ever before. This shift was designed to provide pre-medical students with more outcome-oriented, cost-conscious prep solutions amid an increasingly competitive and financially challenging medical school landscape. What's New Live Courses Before: Blueprint MCAT Live Course with no score guarantee (6-9 months of access) Price: $2549-$3599 Now: Blueprint MCAT 515+ Course with a minimum MCAT score guarantee of 515 (6-12 months of access) Price: $2999-$3599 Self-Paced Courses Before: Blueprint MCAT Self-Paced 6-month Course Price: $1975 Now: Blueprint MCAT Self-Paced 6-month Course Price: $1499 New: Blueprint MCAT Self-Paced 3-month Course Price: $1199 By replacing the basic Blueprint MCAT Live Course, all students opting for live instruction now receive the added benefit of a score guarantee. This ensures either a 515 on their official MCAT or a 15-point improvement from their diagnostic exam performance. The update reflects Blueprint's focus on student outcomes, innovative AI-enhanced MCAT prep solutions, and long-term affordability, while strengthening its competitive position as a premium test prep provider in the medical education space. "We know how high the stakes are for future doctors," said Matt Riley, CEO of Blueprint Prep. "By aligning pricing to results, we're helping students navigate one of the most pivotal steps in the medical school admissions process with greater confidence and less risk." A Response to Rising Admissions Pressure This update comes as the average MCAT score for matriculants rose to just under 512 (511.8) in the most recent cycle, according to the Association of American Medical Colleges (AAMC). Out of the 51,946 students who applied to U.S. medical schools last cycle, only 23,156 actually matriculated. For more selective programs—particularly tuition-free or scholarship-driven institutions like NYU Grossman or Johns Hopkins—average MCAT scores hover around 519. This challenge is further highlighted by potential federal changes to student loan forgiveness and borrower limits, which could significantly impact medical school affordability if approved. Additionally, a single MCAT retake can add months to the admissions process and thousands of dollars in additional expenses, making guaranteed, high-quality prep not just a convenience but a necessity. By expanding access timelines and anchoring all its live courses to a 515+ score standard, Blueprint MCAT is directly addressing the growing call for efficient, high-yield, low-risk preparation models. "I graduated with honors but my GPA wasn't high enough for me to feel very competitive," said Blueprint MCAT 515+ student Madeline. "Getting a 519 MCAT score thanks to Blueprint really helped me and my confidence by knowing that my grades or my MCAT score wouldn't be what held me back from my goals." By delivering scalable, evidence-based learning solutions, Blueprint MCAT aims to continue striking the perfect balance between empowering students and supporting their growth. For more information or to enroll, visit About Blueprint Prep Founded in 2005, Blueprint Prep is the leading platform for high-stakes test prep in the U.S., offering live and self-paced online courses, private tutoring, self-study materials, and application consulting services for pre-law, pre-med, and medical school students, as well as Qbanks, tutoring, and live study groups for residents, practicing physicians, PAs, RNs, and NPs. Blueprint Prep leverages a unique approach that combines engaging video lectures, unparalleled expertise in content creation, the latest adaptive learning technology, and personalized study planning tools. Blueprint Prep has produced unrivaled results, including industry-leading score increases for its pre-law and pre-med students taking the LSAT and MCAT. Learn more at View original content to download multimedia: SOURCE Blueprint Test Preparation LLC Sign in to access your portfolio
Yahoo
6 hours ago
- Yahoo
Clinii Launches Clinii Connect-AI to Transform Patient Communication and Documentation in Chronic Care Programs
NEW YORK, June 11, 2025--(BUSINESS WIRE)--Clinii, a leader in AI-powered Chronic Care Management platforms, today announced the launch of Clinii Connect-AI, a fully native add-on to its core care management platform. Developed entirely in-house, Clinii Connect-AI replaces third-party tools and outdated phone systems with embedded, real-time communication and intelligent automation—all seamlessly integrated into the Clinii interface. With Clinii Connect-AI, care coordinators can manage two-way messaging, web-based voice calls, AI-generated summaries, guided call screens, sentiment tracking, and task creation—all directly from within the Clinii platform. No external software or plug-ins are required. This unified experience enhances what is already one of the industry's most comprehensive solutions for Chronic Care Management (CCM) at scale. "This is more than a communication feature—it's a purpose-built tool designed specifically for the needs of chronic care programs," said Peri Avitan, CEO of Clinii. "While many generic platforms exist, we chose to build something fundamentally different—developed 100% in-house with no third-party dependency. Clinii Connect-AI is intelligent, efficient, and fully aligned with real-world care delivery." Clinii Connect-AI addresses common inefficiencies in care coordination, including limited documentation, lack of visibility into patient sentiment, and time-consuming post-call workflows. With this add-on, every interaction becomes a traceable, billable, and actionable touchpoint—without leaving the platform. Clinii's enterprise customers have already started integrating Clinii Connect-AI into daily operations, using its real-time communication and AI-powered documentation to streamline workflows and improve billing compliance. Key Features of Clinii Connect-AI: Two-Way Messaging: SMS and in-app chat fully integrated with the patient record Embedded Voice Calling: HIPAA-compliant, web-based voice calls with in-call messaging and recording controls AI-Powered Call Guides: Guided call screens that scan care plans, clinical notes, and medications to help coordinators lead focused, compliant conversations Real-Time Summarization: Automated transcription, summaries, and structured clinical notes Sentiment Analysis: Tone detection to flag high-risk or emotionally charged conversations Task Automation: Follow-up items are extracted and converted into care team tasks A short demo video is available at: Clinii Connect-AI will be available to all customers starting Tuesday, June 17, 2025. About CliniiClinii is a digital health company transforming Chronic Care Management through AI-powered automation, workflow integration, and scalable communication. Clinii enables healthcare organizations to deliver compliant, efficient, and patient-centered care at scale. View source version on Contacts media@ |
Gizmodo
6 hours ago
- Gizmodo
After Slashing Thousands of Jobs, Trump's FDA Wants to Use AI to Rapidly Approve New Drugs
AI is slowly permeating all corners of the federal government, including the Food and Drug Administration, where, according to a newly released paper, its top brass now wants to use automation to more 'efficiently' approve new drugs. An article recently published in the Journal of the American Medical Association (JAMA) by Dr. Vinay Prasad, the FDA's director of a subagency that deals with vaccines, lays out a vision for revamping the agency that will supposedly 'increase efficiency' at the agency that regulates what you eat and drink. According to that article, a big way to make the agency more efficient is to use AI to do tasks that humans previously worked on. Specifically, it suggests using automation to speed up the drug approval process. 'The advent of generative artificial intelligence (AI) holds several promises to modernize the FDA and radically increase efficiency in the review process,' the paper reads, while noting that the agency has already implemented a pilot program that involves first 'AI-assisted scientific review.' The article also speaks of a need to 'reevaluate legacy processes at the agency that slow down decisions and do not increase safety.' The study also claims it is looking to find ways to use technology to avoid 'animal cruelty' at the agency. It has supposedly done this by developing 'a road map to reduce animal testing using AI-based computational modeling to predict toxicity-leveraging chip technology.' All of this news comes not long after the FDA purged thousands of staffers from its ranks, including those responsible for reviewing food safety. Now, in what has become a typical pivot for organizations looking to integrate AI, roles previously held by humans seem like they're being automated. The article also suggests the use of 'big data' to help better assess how drug products are developed and reviewed. 'In the past, randomized clinical trials were the sole method used to determine if a product was safe and effective,' the article reads. 'Advances in causal inference in nonrandomized data, including the use of target trials, which attempt to balance confounding and time zero, have [the] potential to yield actionable causal conclusions, in many cases at lower cost.' AI has been spread throughout other parts of the government, as the administration's supposed 'efficiency' mandate looks for newfangled methods to 'streamline' bureaucratic processes. If AI could technically help speed up some bureaucratic processes, a quick look at the way automation rollout is being handled at other agencies doesn't necessarily inspire confidence in the initiative, particularly when it comes to an agency tasked with overseeing drugs that go into Americans' bodies. When it comes to new drugs, there are always guinea pigs involved in the process; now AI's impact will have to be factored into the effectiveness of the latest tests.
